On this episode of Stock Movers:
- NatWest raised its guidance for the year after beating estimates in the 3Q, delivering its highest earnings in at least a decade.
- GSK shares dropped as approval of the British pharma company’s blood cancer drug for a later-than-expected treatment line raised concerns about the medicine’s sales potential.
- Accor shares rose after 3Q earnings in which the hotelier raised its guidance on the back of improved cost discipline. It also announced a new €100 million buyback in 4Q.

On this episode of Stock Movers: - NatWest raised its guidance for the year after beating estimates in the 3Q, delivering its highest earnings in at least a decade. - GSK shares dropped as approval of the British pharma company&rsquo;s blood cancer drug for a later-than-expected treatment line raised concerns about the medicine&rsquo;s sales potential. - Accor shares rose after 3Q earnings in which the hotelier raised its guidance on the back of improved cost discipline. It also announced a new &euro;100 million buyback in 4Q.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

NatWest Rises, GSK Drops, Accor Up 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/c94338e0-5eac-4fce-8d7c-b38000956411/transcript

Advertisement